Pulmonx Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $97.1M
- Price
- $2.26
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.74%
- Volume
- 610.2K
About
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Quick stats
Shares outstanding42.9M
Computed float39.1M
Float / shares91.1%
Cash runway (months)18.2
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001127537
Websitehttps://pulmonx.com
AI Summary
AI-generated1/14
standardmixedearnings
Pulmonx Reports Second Quarter 2026 Financial Results
Pulmonx reported Q2 2026 revenue of $22.8 million, down 5% year-over-year, with U.S. revenue declining 4% and international revenue falling 6% on a constant currency basis due to a lack of sales into China.
Despite the revenue decline, the company achieved a record gross margin of 78% and reduced its net loss by 34% to $10.1 million, driven by a 16% decrease in operating expenses.
Management reaffirmed full-year revenue guidance of $90 million to $92 million and expects total operating expenses to fall between $109 million and $111 million.
Red flags
- Revenue decreased 5% year-over-year
- International revenue decreased 9% on constant currency basis due to lack of sales into China
- Cash, cash equivalents, and marketable securities expected to decrease by approximately $23 million in 2026